Currently, 12 clinical trials are recruiting GBM patients to evaluate CAR T cell therapy against B7 family member B7-H3 (NCT04385173, NCT04077866), CD147, HER2 (NCT03389230), IL13Rα2 (NCT04003649, NCT04661384, NCT02208362), matrix metallopeptidase 2 (MMP2; NCT04214392) and NKG2D (NCT04717999). Here, IL13RA2 is linked to glioblastoma.